CorMedix Reports Strong Q1 Revenue & Net Income; Material Weakness Persists, DefenCath Reimbursement to Decline
CRMD sits 43% above its 52-week low of $6.125.
Summary
CorMedix posted strong Q1 2026 financial results, but faces ongoing internal control issues and an anticipated decline in DefenCath reimbursement later this year, while also executing a share repurchase.
Key Events · Earnings and Guidance · CRMD
-
Strong Q1 Financial Performance
CorMedix reported Q1 2026 total revenue of $127.4 million, a 226% increase year-over-year, and net income of $38.6 million, up 87%, largely due to the Melinta acquisition and DefenCath sales.
-
DefenCath Reimbursement Headwind Expected
The company anticipates a significant reduction in DefenCath net pricing in the second half of 2026 due to a transition in CMS reimbursement methodology, though 2027 payments could increase.
-
Persistent Material Weakness in Internal Controls
The material weakness in internal control over financial reporting, previously disclosed in the 2025 10-K, remains unremediated as of March 31, 2026.
-
Share Repurchase Program Activity
CorMedix repurchased 1.6 million shares for $11.1 million during the first quarter of 2026 under its $75 million authorization, with $63.9 million remaining.
Analysis · CRMD · Life Sciences
CorMedix Inc. reported robust first-quarter 2026 financial results, with significant increases in revenue and net income, primarily driven by the Melinta acquisition and strong DefenCath sales. However, the company continues to report a material weakness in its internal controls over financial reporting, which remains unremediated. A notable future headwind is the expected significant reduction in DefenCath net pricing in the second half of 2026 due to a transition in CMS reimbursement methodology. The company also actively repurchased shares under its authorized program.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRMD was trading at $8.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $588.2M. The 52-week trading range was $6.13 to $17.43. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.